Network-Based Identification of Genetic Effect of SARS-CoV-2 Infections on Idiopathic Pulmonary Fibrosis Patients
September 2020
in “
Briefings in Bioinformatics
”
Studysummary This study identified shared genes and pathways in idiopathic pulmonary fibrosis patients with COVID-19, suggesting these may increase mortality and pointing to potential drug targets for treatment. Our plain-language summary of this paper — not a Tressless recommendation.
The study investigated the genetic effects of SARS-CoV-2 on idiopathic pulmonary fibrosis (IPF) patients using bioinformatics tools to analyze gene expression data. It identified 11 common differentially expressed genes (DEGs) between COVID-19 and IPF, including SAA2, MMP9, and ICAM1, and highlighted five hub genes with significant interactions in protein-protein interaction networks. The research suggested that SARS-CoV-2 might worsen IPF by affecting specific genetic pathways and identified potential drug candidates, such as parthenolide and miglitol, for treating both conditions. The study emphasized the importance of considering genetic factors in managing COVID-19 in individuals with pre-existing pulmonary conditions, although it acknowledged limitations due to the small sample size and the novelty of SARS-CoV-2.